Phase II study of spirogermanium in metastatic prostate cancer.
D000368:Aged; D000970:Antineoplastic Agents / Q000633:toxicity*; D004341:Drug Evaluation; D005857:Germanium / Q000627:therapeutic use / Q000633:toxicity*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013141:Spiro Compounds / Q000627:therapeutic use / Q000633:toxicity*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium